Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Stem cell company Neuralstem has announced that the European Patent Office has granted the company a European patent covering the isolation, propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals.
Subscribe to our email newsletter
The European patent has been validated in several European countries including France, Germany, Ireland, Spain, Sweden, Switzerland and the UK.
Neuralstem’s patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia.
Richard Garr, Neuralstem’s CEO, said: “We are pleased to see our core technology patent validated in these European countries. We expect this to be the first of many as our entire patent portfolio makes its way through the European process.”